homepage-top-section

Bellus focuses on improving the lives of individuals suffering from persistent cough. In April this year, GSK reached an agreement for the acquisition of Bellus Health. The takeover comprises the

It also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The firm raised the amount from Syncona Investment Management, and Cambridge Innovation Capital. Proceeds

As part of the deal, both the entities will be involved in research activities to detect and improve LENSai in silico-generated antibodies. These antibodies are being developed as

The company claimed that its 10mL presentation is the only FDA-approved ready-to-administer 10mL pre-filled syringe available. Nexus Pharmaceuticals CEO and president Usman Ahmed said: “We are pleased to

Earlier, TMB-001 received orphan drug designation from the EC to treat autosomal recessive congenital ichthyosis (ARCI). Timber Pharmaceuticals chairman and CEO John Koconis said: “We are pleased to

Xspray Pharma will maintain financial and strategic control and grant exclusive commercialisation access to Eversana for supporting its Dasynoc launch. Dasynoc, pending approval from the Food and Drug

SAGE-718 is a first-in-class NMDA receptor positive allosteric modulator (PAM) as well as lead neuropsychiatric drug candidate. It is in development as a potential oral therapy for cognitive

Said to be the company’s first combination vaccine candidate, IVX-A12 targets RSV as well as hMPV, which are two of the top five causes of pneumonia in adult

The regulatory agency has ascertained that the application is sufficiently finished to allow a substantive review. Valneva, a specialty vaccine company, stated that the review is classified as